A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Issue 45 (29th October 2021)

• Record Type: Journal Article
• Authors: Moore, Kristine A.; Ostrowsky, Julia T.; Kraigsley, Alison M.; Mehr, Angela J.; Bresee, Joseph S.; Friede, Martin H.; Gellin, Bruce G.; Golding, Josephine P.; Hart, Peter J.; Moen, Ann; Weller, Charlotte L.; Osterholm, Michael T.; Ampofo, William; Barclay, Wendy; Cavaleri, Marco; Cohen, Cheryl; Cowling, Benjamin; Cox, Rebecca; Gust, Ian; Innis, Bruce; Kang, Gagandeep; Katz, Jacqueline; Krammer, Florian; Pitisuttithum, Punnee; Post, Diane; Rudenko, Larisa; Siqueira, Marilda; Weir, Jerry
• Is Part Of: Vaccine. Volume 39:Issue 45(2021)
• Page Start: 6573
• Page End: 6584
• Publication Date: 2021-10-29
• Subjects: Influenza -- Pandemic preparedness -- Seasonal influenza vaccines -- Universal influenza vaccines -- Broadly protective influenza vaccines -- Roadmap; ABS Access and Benefit Sharing -- ACT Access to COVID-19 Tools -- ADCC antibody-dependent cellular cytotoxicity -- CARB-X biopharmaceutical accelerator for combating antibiotic resistant bacteria -- CEPI Coalition for Epidemic Preparedness Innovations -- CIDRAP Center for Infectious Disease Research and Policy -- CIVICs Collaborative Influenza Vaccine Innovation Centers -- COBRA computationally optimized broadly reactive antigen -- CHIVIM controlled human influenza virus infection model -- EU European Union -- FVVA full value of vaccine assessment -- GISRS Global Influenza Surveillance and Response System -- HAI hemagglutination-inhibition -- HA hemagglutinin -- HVAC heating, ventilation, and air conditioning -- IIV inactivated influenza vaccines -- IVR Influenza Vaccines Research and Development (R&D) Roadmap -- LAIV live-attenuated influenza vaccines -- LMICs low- and middle-income countries -- ME&A monitoring, evaluation, and adjustment -- NA neuraminidase -- NIAID US National Institute of Allergy and Infectious Diseases -- R&D Research and Development -- SME subject matter expert -- WHO World Health Organization; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.08.010
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.